摘要
中风被认为是与社会负担和巨大经济损失相关的非常重要的公共卫生问题之一。已经显示出很少有治疗该疾病的治疗方法。在这方面,本发明的治疗平台旨在获得神经保护,再灌注和神经恢复。在这些疗法中,基于再生医学的疗法已经作为中风疗法的新方法出现。透明质酸(HA)是一种新的候选药物,可以作为基于再生医学的疗法用于中风的治疗。 HA是由二糖重复元件(N-乙酰基-D-葡糖胺和D-葡糖醛酸)组成的糖胺聚糖。多条证据表明,HA在正常组织中具有关键作用。它可以在不同的生理和病理生理状况(例如水稳态,多种耐药性,炎症过程,肿瘤发生,血管生成以及细胞外基质的粘弹性变化)中发挥关键作用。 HA具有非常重要的理化性质,即反应性官能团的可用性及其溶解性,这使其成为用于再生医学的生物相容性材料。鉴于HA基生物支架和生物材料不会引起炎症或过敏,并且具有亲水性,因此它们可用作软组织填充剂和可注射的真皮填充剂。多项研究表明,HA可以作为中风治疗的新疗法。这些研究证明,HA和基于HA的疗法通过影响中风相关过程发挥其药理作用。在这里,我们总结了细胞外基质在中风发病机理中的作用。此外,我们重点介绍了基于HA的中风治疗方法。
关键词: 中风,细胞外基质,透明质酸,再生医学,治疗,中枢神经系统。
Current Molecular Medicine
Title:Hyaluronic Acid and Regenerative Medicine: New Insights into the Stroke Therapy
Volume: 20 Issue: 9
关键词: 中风,细胞外基质,透明质酸,再生医学,治疗,中枢神经系统。
摘要: Stroke is known as one of the very important public health problems that are related to societal burden and tremendous economic losses. It has been shown that there are few therapeutic approaches for the treatment of this disease. In this regard, the present therapeutic platforms aim to obtain neuroprotection, reperfusion, and neuro recovery. Among these therapies, regenerative medicine-based therapies have appeared as new ways of stroke therapy. Hyaluronic acid (HA) is a new candidate, which could be applied as a regenerative medicine-based therapy in the treatment of stroke. HA is a glycosaminoglycan composed of disaccharide repeating elements (N-acetyl-Dglucosamine and D-glucuronic acid). Multiple lines of evidence demonstrated that HA has critical roles in normal tissues. It can be a key player in different physiological and pathophysiological conditions such as water homeostasis, multiple drug resistance, inflammatory processes, tumorigenesis, angiogenesis, and changed viscoelasticity of the extracellular matrix. HA has very important physicochemical properties i.e., availability of reactive functional groups and its solubility, which make it a biocompatible material for application in regenerative medicine. Given that HAbased bioscaffolds and biomaterials do not induce inflammation or allergies and are hydrophilic, they are used as soft tissue fillers and injectable dermal fillers. Several studies indicated that HA could be employed as a new therapeutic candidate in the treatment of stroke. These studies documented that HA and HA-based therapies exert their pharmacological effects via affecting stroke-related processes. Herein, we summarized the role of the extracellular matrix in stroke pathogenesis. Moreover, we highlighted the HA-based therapies for the treatment of stroke.
Export Options
About this article
Cite this article as:
Hyaluronic Acid and Regenerative Medicine: New Insights into the Stroke Therapy, Current Molecular Medicine 2020; 20 (9) . https://dx.doi.org/10.2174/1566524020666200326095837
DOI https://dx.doi.org/10.2174/1566524020666200326095837 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Vascular Cell Senescence in Atherosclerosis: Antisenescence as a Novel Therapeutic Strategy for Vascular Aging
Current Vascular Pharmacology Meet Our Editorial Board Member
Current Vascular Pharmacology Poloxamer 188 (P188) as a Membrane Resealing Reagent in Biomedical Applications
Recent Patents on Biotechnology Screening for Rare Genetic Variants Associated with Atherosclerosis: Opportunity for Personalized Medicine
Current Vascular Pharmacology Role of Quality Management System (QMS) for Effective Regulatory Compliance
Applied Clinical Research, Clinical Trials and Regulatory Affairs Pharmacoepigenomics: An Interplay of Epigenetic Modulation of Drug Response and Modulation of the Epigenome by Drugs
Current Pharmaceutical Design Stearoyl-CoA Desaturase-1 and the Metabolic Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic Disorders ACKNOWLEDGEMENT
Cardiovascular & Hematological Agents in Medicinal Chemistry Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Induced Pluripotent Stem Cells as a Model for Accelerated Patient- and Disease-specific Drug Discovery
Current Medicinal Chemistry Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets miR-135a Suppresses Calcification in Senescent VSMCs by Regulating KLF4/STAT3 Pathway
Current Vascular Pharmacology The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology Novel Targets of Metformin in Cardioprotection: Beyond the Effects Mediated by AMPK
Current Pharmaceutical Design Current Concepts of Immunopathogenesis, Diagnosis and Therapy in Whipples Disease
Current Medicinal Chemistry Chronic Heart Failure and Comorbid Renal Dysfunction - A Focus on Type 2 Cardiorenal Syndrome
Current Cardiology Reviews Minocycline Inhibits mTOR Signaling Activation and Alleviates Behavioral Deficits in the Wistar Rats with Acute Ischemia stroke
CNS & Neurological Disorders - Drug Targets Role of Microfluidics in Blood-Brain Barrier Permeability Cell Culture Modeling: Relevance to CNS Disorders
CNS & Neurological Disorders - Drug Targets Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial
Current Rheumatology Reviews Novel Molecular Targets for the Prevention of Fetal Alcohol Syndrome
Recent Patents on CNS Drug Discovery (Discontinued)